MiMedx Group (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 58,300 Shares

MiMedx Group, Inc (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider directly owned 236,982 shares in the company, valued at $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

MiMedx Group Price Performance

NASDAQ MDXG traded up $0.27 during midday trading on Monday, hitting $7.71. The company had a trading volume of 935,066 shares, compared to its average volume of 708,756. The company has a market capitalization of $1.14 billion, a PE ratio of 28.56 and a beta of 1.70. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $7.03 and a 200-day moving average price of $6.82. MiMedx Group, Inc has a twelve month low of $5.79 and a twelve month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. MiMedx Group had a return on equity of 28.35% and a net margin of 10.38%.The company had revenue of $67.69 million for the quarter. As a group, analysts anticipate that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald raised their price objective on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Institutional Trading of MiMedx Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trigran Investments Inc. raised its holdings in MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after purchasing an additional 790,901 shares during the last quarter. Millennium Management LLC boosted its position in shares of MiMedx Group by 93.9% during the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after purchasing an additional 596,016 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in MiMedx Group by 5,332.5% in the second quarter. Ameriprise Financial Inc. now owns 559,058 shares of the company’s stock valued at $3,416,000 after buying an additional 548,767 shares during the period. Meros Investment Management LP boosted its holdings in shares of MiMedx Group by 107.7% during the 1st quarter. Meros Investment Management LP now owns 820,605 shares of the company’s stock worth $6,237,000 after buying an additional 425,531 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of MiMedx Group during the 2nd quarter valued at $2,317,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.